bioAffinity Technologies, Inc. - BIAF STOCK NEWS

Welcome to our dedicated page for bioAffinity Technologies news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Technologies stock.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) is a pioneering biotechnology company dedicated to addressing the critical need for the early detection and targeted treatment of cancer and lung diseases. The company develops proprietary, noninvasive diagnostic tests and cancer therapeutics that focus on the cellular level, which has the potential to significantly improve patient outcomes.

One of the company’s leading innovations is the CyPath® Lung test, a noninvasive diagnostic tool designed to detect early-stage lung cancer. This test employs flow cytometry technology to analyze sputum samples, which can dramatically increase diagnostic accuracy, reduce the need for invasive procedures, and lower medical costs while enhancing patient comfort and survival rates. CyPath® Lung has been licensed by Precision Pathology Services for further development and commercial sale as a laboratory-developed test.

Recent company milestones include a securities purchase agreement with institutional investors, announced on March 6, 2024, by WallachBeth Capital LLC. This agreement involves a registered direct offering and a concurrent private placement, expected to raise approximately $2.5 million. The proceeds will support the company's ongoing research, development activities, and potential commercialization efforts.

Financially, bioAffinity Technologies is actively engaging with institutional investors to secure funding necessary for its ambitious projects. The company’s efforts are supported by an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and the strategic guidance of WallachBeth Capital, which provides comprehensive capital market and investment banking services tailored to the healthcare sector.

Through its innovative approach and strong industry partnerships, bioAffinity Technologies aims to revolutionize cancer diagnosis and treatment, ultimately improving survival rates and quality of life for patients worldwide.

01/05/2024 09:00 AM

News

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Rhea-AI Summary

RedChip Companies will air interviews with bioAffinity Technologies, Inc. (BIAF) and BioVie, Inc. (BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. BioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment, with a focus on lung cancer detection. The company's flagship product, CyPath® Lung, has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. The company also holds extensive U.S. and international patents and has strong insider ownership at 39%. BioVie, Inc. is a clinical-stage company developing therapies for Alzheimer's, Parkinson's, refractory ascites, and HRS-AKI. The company recently reported positive trending data from a Phase 3 trial in Alzheimer's and has plans to launch Phase 3 trials in 2024 for Alzheimer's, Parkinson's, and Ascites.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.79%

Tags

12/05/2023 08:00 AM

News

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

Rhea-AI Summary

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the appointment of Jamie Platt, Ph.D., to its Board of Directors, effective Dec. 1, 2023. Dr. Platt brings two decades of experience in diagnostic technologies and has been instrumental in two M&A exits for diagnostic companies in 2022, resulting in a combined value of nearly $1 billion. She has extensive experience in expanding product market share in the diagnostics market. Dr. Platt's appointment is expected to drive bioAffinity's growth and success, particularly in commercializing CyPath® Lung, their noninvasive test for the early detection of lung cancer.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.81%

Tags

11/30/2023 08:00 AM

News

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

Rhea-AI Summary

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year. The CMS payment determination is a major milestone that facilitates reimbursement by both Medicare and private payers, making the test more attractive to physicians and their patients at high risk for lung cancer. The test showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in patients with small lung nodules less than 20 millimeters.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

22.96%

Tags

11/28/2023 08:00 AM

News

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Rhea-AI Summary

BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that David Elzi, Ph.D., has been named to the Membership Committee of the American Society for Cell Biology (ASCB). ASCB is an international organization of cell biologists dedicated to advancing scientific discovery and improving education. Dr. Elzi will host a roundtable at Cell Bio 2023 to discuss transferable skills for transitioning into the biotech industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.35%

Tags

11/15/2023 08:00 AM

News

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

Rhea-AI Summary

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) launches a campaign with the American Cancer Society to increase lung cancer screening in Texas. The 'Power of Three' campaign aims to support local programs and emphasizes the importance of joining forces in the fight against lung cancer.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.8%

Tags

11/14/2023 04:01 PM

News

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

BIAF - bioAffinity Technologies, Inc. reported financial results for the third quarter of 2023 and provided a business update. The company's subsidiary acquired Village Oaks Pathology Services, and CMS released a preliminary payment decision for CyPath® Lung. The U.S. Department of Defense purchased CyPath® Lung tests for an observational study. Revenue for the third quarter of 2023 increased to $298,484, and net loss was $2.3 million. The company expects to generate between $2.1 and $2.3 million in net revenues for 2023 and between $8.4 and $9.0 million over the next 12 months.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.8%

Tags

11/06/2023 08:00 AM

News

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

Rhea-AI Summary

bioAffinity Technologies, Inc. has appointed Dallas J. Coleman as National Director of Sales. Coleman has over 15 years of experience in medical sales and marketing. He will be responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. His expertise is expected to help drive the expansion of their pilot market launch across Texas and pave the way for the national rollout of CyPath® Lung.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.04%

Tags

10/10/2023 08:00 AM

News

bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference

Rhea-AI Summary

bioAffinity Technologies, Inc. CEO Maria Zannes to present corporate update at Dawson James Small Cap Growth Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.27%

Tags

09/19/2023 08:00 AM

News

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

Rhea-AI Summary

bioAffinity Technologies acquires Precision Pathology Services to support commercialization of CyPath® Lung test. The acquisition cost $3.5 million in cash and stock. The transaction aims to accelerate market uptake, support FDA pivotal trial, and develop additional tests. Precision Pathology offers a range of laboratory services. Dr. Roby Joyce joins bioAffinity's board of directors. Conference call at 4:30 p.m. ET today.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.63%

Tags

09/07/2023 08:00 AM

News

bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

bioAffinity Technologies to present corporate update and hold meetings with investors at H.C. Wainwright conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.58%

Tags

FAQ

What is the current stock price of bioAffinity Technologies (BIAF)?

The current stock price of bioAffinity Technologies (BIAF) is $0.7912 as of January 28, 2025.

What is the market cap of bioAffinity Technologies (BIAF)?

The market cap of bioAffinity Technologies (BIAF) is approximately 11.2M.

What does bioAffinity Technologies, Inc. specialize in?

bioAffinity Technologies specializes in developing noninvasive diagnostic tests and targeted cancer treatments at the cellular level.

What is CyPath® Lung?

CyPath® Lung is a noninvasive test developed by bioAffinity Technologies for the early detection of lung cancer using flow cytometry technology.

Who has licensed CyPath® Lung for development?

CyPath® Lung has been licensed by Precision Pathology Services for further development and commercial sale.

What recent financial agreement has bioAffinity Technologies entered into?

The company has entered into a securities purchase agreement with institutional investors, involving a registered direct offering and a concurrent private placement.

What is the anticipated financial benefit of the recent securities offering?

The offering is expected to raise approximately $2.5 million, excluding potential proceeds from warrant exercises.

Who is assisting bioAffinity Technologies with their financial transactions?

WallachBeth Capital LLC is acting as the sole placement agent for the company's financial transactions.

What are the future plans for bioAffinity Technologies?

bioAffinity Technologies plans to continue the development and commercialization of their diagnostic tests and cancer therapeutics, leveraging the proceeds from recent financial transactions.

How does CyPath® Lung improve patient outcomes?

CyPath® Lung improves patient outcomes by increasing diagnostic accuracy, reducing the need for invasive procedures, and lowering medical costs.

Where can I find more information about the registered direct offering?

Details about the registered direct offering can be found in the prospectus supplement filed with the SEC, available on their website.

What technology does bioAffinity Technologies focus on for their products?

The company focuses on technology that targets cancer cells and cell populations indicative of disease, primarily using flow cytometry in their diagnostics.